Murphy signs bill scheduling tianeptine as Schedule II controlled substance in New Jersey - WRNJ Radio
New Jersey Governor Murphy signed a bill classifying tianeptine as a Schedule II controlled substance, effective immediately. This imposes strict regulatory requirements on pharmacies and prescribers handling tianeptine.
Aforeworn detected this change in the Pharmacy & Controlled Substances space on July 16, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Independent pharmacies, retail chains, compounding pharmacies, long-term-care pharmacies in New Jersey should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediately; no grace period.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmacy & Controlled Substances continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Tianeptine is now a Schedule II controlled substance under New Jersey law, requiring DEA registration, secure storage, strict recordkeeping, and e-prescribing for new prescriptions.
Who it affects
Independent pharmacies, retail chains, compounding pharmacies, long-term-care pharmacies in New Jersey
What you must do
Ensure all tianeptine products are stored, dispensed, and recorded as Schedule II substances. Update pharmacy management systems, train staff, and verify prescriber DEA registration.
Deadline
Immediately; no grace period.
Never miss a change like this again
Aforeworn watches Pharmacy & Controlled Substances around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmacy & Controlled Substances
- TX HB 7: Relating to prohibitions on the manufacture and provision of abortion-inducing drugs, including the jurisdiction of and effect of certain judgments by courts within and outside this state with respect to the manufacture and provision of those drugs, and to protections from certain counteractions under the laws of other states and jurisdictions; authorizing qui tam actions.
- US-CONGRESS HR7895: PBM Kickback Prohibition Act
- IL HB0004: MEDICAID-PHARMACY SERVICES
- Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661
- Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications